| Over a week ago | ||||
BofA analyst Kevin… BofA analyst Kevin Fischbeck initiated coverage of AMN Healthcare with a Buy rating and $70 price target. The analyst is positive on the company's scale and "diverse offerings" as it heads into a period of normalized utilization, which he believes warrants a "premium multiple" relative to its historical range of 7- to 12- times expected forward EBITDA. Fischbeck models his price target on 15-1-times expected 2021 EBITDA estimate. | ||||
Virtual Meetings to be… Virtual Meetings to be held September 21-22 hosted by Truist. | ||||
Virtual Meetings to be… Virtual Meetings to be held September 21-22 hosted by Truist. | ||||
| Over a month ago | ||||
Virtual Meetings to be… Virtual Meetings to be held September 21-22 hosted by Truist. | ||||
BMO Capital analyst… BMO Capital analyst Jeffrey Silber raised the firm's price target on AMN Healthcare to $65 from $50 and keeps an Outperform rating on the shares. The analyst cites the company's Q2 earnings beat driven by better-than-expected travel nursing growth, while its Q3 guidance topped consensus and highlighted its order visibility. | ||||
Q3 gross margin is… Q3 gross margin is expected to be 33.0-33.5%, operating margin is expected to be above 7%, and adjusted EBITDA margin is expected to be greater than 13%. | |
Reports Q2 revenue… Reports Q2 revenue $608.4M, consensus $560.74M. "Our healthcare professionals and the entire AMN team are doing an exceptional job of pivoting and leaning in to help patients receive the compassionate care needed as our country navigates through this crisis, and we are prioritizing their health and well-being," said CEO Susan Salka. "AMN's long-standing commitment to diversity, equality, equity and inclusion has been a critical part of our culture and collaboration with stakeholders. Our dedication in fighting for social justice and against racism has been fortified over these last few months, and AMN is taking greater action to support our team members, healthcare professionals, clients and communities. In this unprecedented business environment, we have adapted our operations and cost structure to be more agile and responsive to the fast-changing needs of our healthcare professionals and clients. We are also continuing to make important investments in our people, processes and technology to further differentiate AMN and enable future growth opportunities," Salka said. |
| Over a quarter ago | ||||
SunTrust analyst Tobey… SunTrust analyst Tobey Sommer upgraded AMN Healthcare to Buy from Hold with a $62 price target. Sommer cites improving weekly travel nurse orders per private companies and his firm's RN job posting data and growing crisis orders for rapid response nurses in hotspots for the upgrade, as well as an expectation for a reversal of near-term share under-performance. The analyst sees earnings power of $5.00 in 2024 vs. the $2.72 consensus estimate in 2020. | ||||
SunTrust analyst Tobey… SunTrust analyst Tobey Sommer upgraded AMN Healthcare to Buy from Hold. | ||||
U.S. District judge… U.S. District judge yesterday granted judgment in favor of AMN Healthcare, ruling that Aya Healthcare failed to prove any anticompetitive behavior by AMN under federal antitrust laws. "AMN Healthcare is thrilled but not surprised by the Court's ruling. We have always known that our business practices are legitimate, lawful, and procompetitive. In an apparent effort to distract us from our mission, Aya filed a meritless lawsuit," said Susan Salka, President and CEO of AMN Healthcare. | ||||